ESMO Targeted Anticancer Therapies Congress 2024: Event announcement

ESMO Targeted Anticancer Therapies Congress 2024: Event announcement

Location: Paris, France

Lugano, Switzerland, 20 February 2024 – The ESMO Targeted Anticancer Therapies Congress 2024 is the annual multi-stakeholder meeting that focuses on the development of novel anticancer therapies and how this can transform the current knowledge and impact clinical care. This event brings together various experts in the early drug development arena, including investigators from academia, investor and regulatory bodies, as well as translational scientists.

The event will be held in Paris, France, between 26-28 February.

New this year

  • Four new special sessions will enrich this year’s scientific programme, with international speakers from the pharmaceutical industry addressing methodological and regulatory challenges in the development and implementation of innovative cancer therapeutics.
    Related content: Session on 26 February, 13:45-15:15 CET; Sessions on 27 February, 11:15-12:45 CET and 13:45-15:15 CET; Session on 28 February, 13:30-15:00 CET

Programme highlights

  • The role of artificial intelligence, machine learning, and digital technology in early phase research: From uncovering new immunotherapy targets with clinical potential to unveiling new potential targeted therapies
    Related content: 1O, 2P, 4P, 5P and session on 27 February, 8:00-8:45 CET

  • Novel perspectives on antibody-drug conjugates: new targets, linkers, payloads and combination with other agents
    Related content: Session on 28 February, 09:15-10:45 CET

  • ctDNA as promising biomarker to predict the patients’ response to treatment and guide experimental therapeutics in phase I trials
    Related content: 85O, 86O, Session on 27 February, 09:15-10:45 CET

Award keynote lectures

The results of more than 110 studies from various parts of the world will be presented and published online as a supplement to ESMO Open. The abstract titles can be viewed through the online programme.

Press accreditation

ESMO welcomes press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities. To apply for press accreditation, please fill out the form available here. Requests for press accreditation should be sent by Friday, 23 February. Please be kindly informed that onsite press accreditation will not be available.

Further information

ESMO Press Office

Regions: Europe, Switzerland, France
Keywords: Health, Medical, People in health research, Policy, Public Dialogue - health


For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...

  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
Copyright 2024 by AlphaGalileo Terms Of Use Privacy Statement